Plain-English translation of NCT07241390 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a large study testing whether a medication called can help prevent serious heart events in people who have established heart disease and/or chronic kidney disease. Half of the participants will receive the medication while the other half receive a placebo (a pill with no active ingredient), and researchers will compare how many serious heart problems occur in each group over about 5 years. Everyone in the study will also continue taking their regular medications as usual.
People with heart disease and chronic kidney disease face a high risk of serious heart complications, and doctors are looking for new treatments that can better protect these patients. This medication is being tested to see whether it can reduce the number of heart attacks, strokes, and other major cardiovascular events in this high-risk population.
You likely qualify if…
You likely don't qualify if…
You will take a daily pill at home—either the new medication or a placebo—in addition to your regular medications. You'll visit the study site periodically over about 5 years for check-ups, blood tests, and heart-related assessments. The study will track whether you experience any serious heart events and compare outcomes between those who received the medication and those who received placebo.
AI-generated summary from trial data · Sep 20, 2026 · Not medical advice
Argentina